{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:35:11Z","timestamp":1789641311315,"version":"4.0.0"},"reference-count":232,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bacterial topoisomerases are enzymes critical for maintaining genomic DNA integrity and ensuring bacterial cell survival, making them ideal targets for antibacterial agents. Bacterial topoisomerase inhibitors, such as quinolones and fluoroquinolones, target two enzymes, DNA gyrase and topoisomerase IV, and inhibit the control of DNA supercoiling\/decatenation, leading to impaired DNA replication and bacterial cell death. Since their initial discovery, many quinolones and fluoroquinolones have been developed with activity against a wide range of bacterial species, contributing significantly to the treatment of various infectious diseases worldwide. Fluoroquinolones such as levofloxacin and ciprofloxacin remain important and effective therapeutic options today due to their broad-spectrum antibacterial activity, chemical stability and high bioavailability. However, side effects of fluoroquinolones have become a concern, leading to warnings being issued in the United States, Europe and the United Kingdom. Furthermore, in many countries, the prevalence of fluoroquinolone-resistant bacteria has been steadily increasing each year, which poses a serious threat to public health. The clinical development of new non-quinolone bacterial topoisomerase inhibitors (for example, zoliflodacin, gepotidacin and fobrepodacin) offers a promising solution to these issues and has the potential to play a crucial role in combating the growing problem of antimicrobial resistance. This review article will discuss the evolution of quinolone and fluoroquinolone antibacterial agents as key topoisomerase inhibitors, examine their current clinical applications and challenges to future development, and explore the potential of new topoisomerase inhibitors.<\/jats:p>","DOI":"10.1093\/jac\/dkag054","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:38:19Z","timestamp":1770122299000},"source":"Crossref","is-referenced-by-count":12,"title":["Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future"],"prefix":"10.1093","volume":"81","author":[{"given":"Daisuke","family":"Fukuda","sequence":"first","affiliation":[{"name":"Vaccines and Infectious Diseases, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Powell","sequence":"additional","affiliation":[{"name":"Antibiotics, GSK , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruni","family":"Mulgirigama","sequence":"additional","affiliation":[{"name":"Antibiotics, GSK , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Vojtek","sequence":"additional","affiliation":[{"name":"Vaccines and Infectious Diseases, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ozeki","sequence":"additional","affiliation":[{"name":"Vaccines and Infectious Diseases, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Vaccines and Infectious Diseases, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Iida","sequence":"additional","affiliation":[{"name":"Vaccines and Infectious Diseases, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Johira","sequence":"additional","affiliation":[{"name":"Vaccines and Infectious Diseases, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kayama","sequence":"additional","affiliation":[{"name":"Vaccines and Infectious Diseases, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kawamatsu","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, Specialty Care, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-0425","authenticated-orcid":false,"given":"Satowa","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026021903541847700_dkag054-B1","doi-asserted-by":"publisher","first-page":"e2000286","DOI":"10.1002\/bies.202000286","article-title":"DNA topoisomerases: advances in understanding of cellular roles and multi-protein complexes via structure-function analysis","volume":"43","author":"McKie","year":"2021","journal-title":"Bioessays"},{"key":"2026021903541847700_dkag054-B2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/genes7120134","article-title":"The causes and consequences of topological stress during DNA replication","volume":"7","author":"Keszthelyi","year":"2016","journal-title":"Genes (Basel)"},{"key":"2026021903541847700_dkag054-B3","doi-asserted-by":"publisher","first-page":"37207","DOI":"10.1074\/jbc.M206663200","article-title":"Failure to relax negative supercoiling of DNA is a primary cause of mitotic hyper-recombination in topoisomerase-deficient yeast cells","volume":"277","author":"Trigueros","year":"2002","journal-title":"J Biol Chem"},{"key":"2026021903541847700_dkag054-B4","doi-asserted-by":"publisher","first-page":"10.1128\/ecosalplus.ESP-0010-2014","DOI":"10.1128\/ecosalplus.esp-0010-2014","article-title":"DNA topoisomerases","volume":"6","author":"Bush","year":"2015","journal-title":"EcoSal Plus"},{"key":"2026021903541847700_dkag054-B5","doi-asserted-by":"publisher","first-page":"R778","DOI":"10.1016\/S0960-9822(06)00403-9","article-title":"DNA topology: topoisomerases keep it simple","volume":"7","author":"Bates","year":"1997","journal-title":"Curr Biol"},{"key":"2026021903541847700_dkag054-B6","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1016\/j.jmb.2019.07.008","article-title":"DNA topoisomerase inhibitors: trapping a DNA-cleaving machine in motion","volume":"431","author":"Bax","year":"2019","journal-title":"J Mol Biol"},{"key":"2026021903541847700_dkag054-B7","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.ejmcr.2021.100017","article-title":"Novel bacterial topoisomerase inhibitors (NBTIs) \u2013 a comprehensive review","volume":"3","author":"Desai","year":"2021","journal-title":"Eur J Med Chem Rep"},{"key":"2026021903541847700_dkag054-B8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/molecules21040268","article-title":"The current case of quinolones: synthetic approaches and antibacterial activity","volume":"21","author":"Naeem","year":"2016","journal-title":"Molecules"},{"key":"2026021903541847700_dkag054-B9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"2026021903541847700_dkag054-B10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1128\/mmbr.61.3.377-392.1997","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones","volume":"61","author":"Drlica","year":"1997","journal-title":"Microbiol Mol Biol Rev"},{"key":"2026021903541847700_dkag054-B11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2174\/156802609789630947","article-title":"Quinolones: action and resistance updated","volume":"9","author":"Drlica","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"2026021903541847700_dkag054-B12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1006\/jmbi.1994.1586","article-title":"The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase","volume":"242","author":"Willmott","year":"1994","journal-title":"J Mol Biol"},{"key":"2026021903541847700_dkag054-B13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1006\/jmbi.2000.4266","article-title":"The complex of DNA gyrase and quinolone drugs on DNA forms a barrier to the T7 DNA polymerase replication complex","volume":"304","author":"Wentzell","year":"2000","journal-title":"J Mol Biol"},{"key":"2026021903541847700_dkag054-B14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1021\/jm01240a021","article-title":"1,8-naphthyridine derivatives. A new class of chemotherapeutic agents","volume":"5","author":"Lesher","year":"1962","journal-title":"J Med Pharm Chem"},{"key":"2026021903541847700_dkag054-B15","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1021\/jm501881c","article-title":"Origins of the quinolone class of antibacterials: an expanded \u201cdiscovery story\u201d","volume":"58","author":"Bisacchi","year":"2015","journal-title":"J Med Chem"},{"issue":"Suppl 1","key":"2026021903541847700_dkag054-B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jac\/dkg208","article-title":"The quinolones: decades of development and use","volume":"51","author":"Emmerson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/jac\/33.4.685","article-title":"Structure-activity and structure-side-effect relationships for the quinolone antibacterials","volume":"33","author":"Domagala","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B18","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone antibiotics","volume":"10","author":"Pham","year":"2019","journal-title":"MedChemComm"},{"key":"2026021903541847700_dkag054-B19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1128\/AAC.17.2.103","article-title":"In vitro antibacterial activity of AM-715, a new nalidixic acid analog","volume":"17","author":"Ito","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B20","doi-asserted-by":"publisher","first-page":"120440","DOI":"10.1016\/j.envpol.2022.120440","article-title":"Fluoroquinolone antibiotics: occurrence, mode of action, resistance, environmental detection, and remediation - a comprehensive review","volume":"315","author":"Bhatt","year":"2022","journal-title":"Environ Pollut"},{"key":"2026021903541847700_dkag054-B21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/00325481.2019.1680052","article-title":"Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents","volume":"132","author":"Bader","year":"2020","journal-title":"Postgrad Med"},{"key":"2026021903541847700_dkag054-B22","doi-asserted-by":"publisher","first-page":"e01515","DOI":"10.1128\/AAC.01515-20","article-title":"Fluoroquinolone versus beta-lactam oral step-down therapy for uncomplicated streptococcal bloodstream infections","volume":"64","author":"Arensman","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B23","doi-asserted-by":"publisher","first-page":"106905","DOI":"10.1016\/j.ijantimicag.2023.106905","article-title":"Respiratory fluoroquinolone monotherapy vs. \u0392-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Choi","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026021903541847700_dkag054-B24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12879-022-07167-y","article-title":"A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011-2020","volume":"22","author":"Dunne","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026021903541847700_dkag054-B25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jgar.2020.10.020","article-title":"Resistance among urinary tract pathogens collected in Europe during 2018","volume":"23","author":"Critchley","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2026021903541847700_dkag054-B26","author":"The AMR One Health Surveillance Committee"},{"key":"2026021903541847700_dkag054-B27","author":"The AMR One Health Surveillance Committee"},{"key":"2026021903541847700_dkag054-B28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jiac.2021.03.012","article-title":"Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: conducted by the Japanese Research Group for urinary tract infections (JRGU)","volume":"27","author":"Wada","year":"2021","journal-title":"J Infect Chemother"},{"key":"2026021903541847700_dkag054-B29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jiac.2019.02.021","article-title":"Second nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by Japanese surveillance committee from 2015 to 2016: antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus","volume":"25","author":"Hayami","year":"2019","journal-title":"J Infect Chemother"},{"key":"2026021903541847700_dkag054-B30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jiac.2024.01.011","article-title":"Third nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2020 and 2021: antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus","volume":"30","author":"Wada","year":"2024","journal-title":"J Infect Chemother"},{"key":"2026021903541847700_dkag054-B31","doi-asserted-by":"publisher","first-page":"a816","DOI":"10.1136\/bmj.a816","article-title":"FDA adds \u201cblack box\u201d warning label to fluoroquinolone antibiotics","volume":"337","author":"Tanne","year":"2008","journal-title":"BMJ"},{"key":"2026021903541847700_dkag054-B32","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B33","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B34","author":"Ross"},{"key":"2026021903541847700_dkag054-B35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"2026021903541847700_dkag054-B36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(25)01953-1","article-title":"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial","volume":"407","author":"Luckey","year":"2026","journal-title":"Lancet"},{"key":"2026021903541847700_dkag054-B37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41429-023-00629-8","article-title":"Antibiotics in the clinical pipeline as of December 2022","volume":"76","author":"Butler","year":"2023","journal-title":"J Antibiot (Tokyo)"},{"key":"2026021903541847700_dkag054-B38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3343\/alm.2024.44.1.92","article-title":"In vitro activity of benzimidazole (SPR719) against clinical isolates of nontuberculous mycobacteria with and without clarithromycin or amikacin resistance","volume":"44","author":"Kim","year":"2024","journal-title":"Ann Lab Med"},{"key":"2026021903541847700_dkag054-B39","author":"ClinicalTrials.gov"},{"key":"2026021903541847700_dkag054-B40","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.3390\/ijms25073764","article-title":"Revealing the interaction mechanism between Mycobacterium tuberculosis GyrB and novobiocin, SPR719 through binding thermodynamics and dissociation kinetics analysis","volume":"25","author":"Qiu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026021903541847700_dkag054-B41","doi-asserted-by":"publisher","first-page":"8941","DOI":"10.1021\/acs.jmedchem.6b00864","article-title":"Discovery of benzothiazole scaffold-based DNA gyrase B inhibitors","volume":"59","author":"Gjorgjieva","year":"2016","journal-title":"J Med Chem"},{"key":"2026021903541847700_dkag054-B42","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1073\/pnas.73.12.4474","article-title":"Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase","volume":"73","author":"Gellert","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026021903541847700_dkag054-B43","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1073\/pnas.75.4.1773","article-title":"Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity","volume":"75","author":"Higgins","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026021903541847700_dkag054-B44","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1074\/jbc.RA119.010245","article-title":"Functional interactions between gyrase subunits are optimized in a species-specific manner","volume":"295","author":"Weidlich","year":"2020","journal-title":"J Biol Chem"},{"key":"2026021903541847700_dkag054-B45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tube.2018.09.001","article-title":"Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis","volume":"113","author":"Kashyap","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"2026021903541847700_dkag054-B46","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1016\/S0021-9258(18)61193-7","article-title":"Mapping the active site tyrosine of Escherichia coli DNA gyrase","volume":"262","author":"Horowitz","year":"1987","journal-title":"J Biol Chem"},{"key":"2026021903541847700_dkag054-B47","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1073\/pnas.74.11.4767","article-title":"Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme","volume":"74","author":"Sugino","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026021903541847700_dkag054-B48","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1128\/jb.88.4.1112-1118.1964","article-title":"Mechanism of action of nalidixic acid on Escherichia coli","volume":"88","author":"Goss","year":"1964","journal-title":"J Bacteriol"},{"key":"2026021903541847700_dkag054-B49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jobm.3620370109","article-title":"Discoordinate gene expression of GyrA and GyrB in response to DNA gyrase inhibition in Escherichia coli","volume":"37","author":"Neumann","year":"1997","journal-title":"J Basic Microbiol"},{"key":"2026021903541847700_dkag054-B50","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1073\/pnas.74.11.4772","article-title":"Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity","volume":"74","author":"Gellert","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026021903541847700_dkag054-B51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1128\/jb.99.1.238-241.1969","article-title":"Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies","volume":"99","author":"Hane","year":"1969","journal-title":"J Bacteriol"},{"key":"2026021903541847700_dkag054-B52","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1073\/pnas.75.12.5960","article-title":"DNA gyrase: subunit structure and atpase activity of the purified enzyme","volume":"75","author":"Mizuuchi","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026021903541847700_dkag054-B53","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/jac\/dkg168","article-title":"Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals","volume":"51","author":"S\u00e1enz","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B54","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1529\/biophysj.105.060202","article-title":"Topoisomerase IV bends and overtwists DNA upon binding","volume":"89","author":"Charvin","year":"2005","journal-title":"Biophys J"},{"key":"2026021903541847700_dkag054-B55","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1101\/gad.11.19.2580","article-title":"Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli","volume":"11","author":"Zechiedrich","year":"1997","journal-title":"Genes Dev"},{"key":"2026021903541847700_dkag054-B56","first-page":"475","article-title":"Oxolinic acid, a new synthetic antimicrobial agent. I. In vitro and in vivo activity","volume":"7","author":"Turner","year":"1967","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5694\/j.1326-5377.1975.tb111283.x","article-title":"Urinary tract infection treated with oxolinic acid","volume":"1","author":"Pearson","year":"1975","journal-title":"Med J Aust"},{"key":"2026021903541847700_dkag054-B58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/jac\/4.3.289","article-title":"In vitro susceptibility studies with piromidic acid","volume":"4","author":"Garcia Rodriguez","year":"1978","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B59","first-page":"117","article-title":"Piromidic acid, a new antibacterial agent: antibacterial properties","volume":"10","author":"Shimizu","year":"1970","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1128\/AAC.4.4.415","article-title":"Compound 64716, a new synthetic antibacterial agent","volume":"4","author":"Wick","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B61","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1128\/AAC.15.2.165","article-title":"Pharmacology of cinoxacin in humans","volume":"15","author":"Black","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B62","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0378-5173(03)00074-7","article-title":"Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall","volume":"256","author":"Grabnar","year":"2003","journal-title":"Int J Pharm"},{"key":"2026021903541847700_dkag054-B63","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1128\/AAC.7.4.441","article-title":"Pipemidic acid: absorption, distribution, and excretion","volume":"7","author":"Shimizu","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B64","doi-asserted-by":"publisher","first-page":"117569","DOI":"10.1016\/j.saa.2019.117569","article-title":"Assessing physical properties of amphoteric fluoroquinolones using phosphorescence spectroscopy","volume":"227","author":"Soldevila","year":"2020","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"2026021903541847700_dkag054-B65","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1128\/AAC.8.2.132","article-title":"Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: In vitro properties","volume":"8","author":"Shimizu","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B66","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1128\/AAC.14.2.240","article-title":"Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids","volume":"14","author":"Inoue","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1128\/AAC.17.2.203","article-title":"In vitro and in vivo antibacterial activity of AB206, a new naphthyridine derivative","volume":"17","author":"Nagate","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1136\/sti.57.1.33","article-title":"In-vitro antigonococcal activity of rosoxacin (win 35213)","volume":"57","author":"Warren","year":"1981","journal-title":"Br J Vener Dis"},{"key":"2026021903541847700_dkag054-B69","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3390\/ani11061514","article-title":"Distribution of flumequine in intestinal contents and colon tissue in pigs after its therapeutic use in the drinking water","volume":"11","author":"Rodr\u00edguez","year":"2021","journal-title":"Animals (Basel)"},{"key":"2026021903541847700_dkag054-B70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0924-8579(00)00192-8","article-title":"The fluoroquinolone antibacterials: past, present and future perspectives","volume":"16","author":"Appelbaum","year":"2000","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"2026021903541847700_dkag054-B71","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/oxfordjournals.jac.a020889","article-title":"Quinolone generations: natural history or natural selection?","volume":"46","author":"Ball","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/jac\/21.1.101","article-title":"A multicentre study of flumequine in the treatment of urinary tract infections","volume":"21","author":"Schena","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B73","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0092-8674(92)90356-H","article-title":"The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication","volume":"71","author":"Adams","year":"1992","journal-title":"Cell"},{"key":"2026021903541847700_dkag054-B74","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates","volume":"6","author":"Bradford","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2026021903541847700_dkag054-B75","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","article-title":"Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: genetic and biochemical evidence for well-balanced dual-targeting","volume":"10","author":"Oviatt","year":"2024","journal-title":"ACS Infect Dis"},{"key":"2026021903541847700_dkag054-B76","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1128\/jb.93.1.71-79.1967","article-title":"Mode of action of novobiocin in Escherichia coli","volume":"93","author":"Smith","year":"1967","journal-title":"J Bacteriol"},{"issue":"Suppl 1","key":"2026021903541847700_dkag054-B77","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1086\/514923","article-title":"Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance","volume":"27","author":"Hooper","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2026021903541847700_dkag054-B78","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1111\/cts.13359","article-title":"Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects","volume":"15","author":"Tiffany","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2026021903541847700_dkag054-B79","doi-asserted-by":"publisher","first-page":"12300","DOI":"10.1074\/jbc.M113.529164","article-title":"Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding","volume":"289","author":"Mustaev","year":"2014","journal-title":"J Biol Chem"},{"key":"2026021903541847700_dkag054-B80","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/ijms24021634","article-title":"A 2.8 \u00e5 structure of zoliflodacin in a DNA cleavage complex with Staphylococcus aureus DNA gyrase","volume":"24","author":"Morgan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026021903541847700_dkag054-B81","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2026021903541847700_dkag054-B82","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1128\/AAC.04456-14","article-title":"Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae","volume":"59","author":"Alm","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B83","doi-asserted-by":"publisher","first-page":"11801","DOI":"10.1073\/pnas.92.25.11801","article-title":"Topoisomerase IV is a target of quinolones in Escherichia coli","volume":"92","author":"Khodursky","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026021903541847700_dkag054-B84","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1021\/acsinfecdis.4c00438","article-title":"Interactions between zoliflodacin and Neisseria gonorrhoeae gyrase and topoisomerase IV: enzymological basis for cellular targeting","volume":"10","author":"Collins","year":"2024","journal-title":"ACS Infect Dis"},{"key":"2026021903541847700_dkag054-B85","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1021\/acsinfecdis.4c00128","article-title":"Gyrase and topoisomerase IV: recycling old targets for new antibacterials to combat fluoroquinolone resistance","volume":"10","author":"Collins","year":"2024","journal-title":"ACS Infect Dis"},{"key":"2026021903541847700_dkag054-B86","doi-asserted-by":"publisher","first-page":"20984","DOI":"10.1074\/jbc.M115.663534","article-title":"Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914","volume":"290","author":"Kern","year":"2015","journal-title":"J Biol Chem"},{"key":"2026021903541847700_dkag054-B87","doi-asserted-by":"publisher","first-page":"e00207","DOI":"10.1128\/AAC.00207-19","article-title":"Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations","volume":"63","author":"Szili","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B88","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ejmech.2013.01.057","article-title":"Antibacterial action of quinolones: from target to network","volume":"66","author":"Cheng","year":"2013","journal-title":"Eur J Med Chem"},{"key":"2026021903541847700_dkag054-B89","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1128\/AAC.01182-12","article-title":"Isolation and quantitation of topoisomerase complexes accumulated on Escherichia coli chromosomal DNA","volume":"56","author":"Aedo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B90","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1128\/AAC.40.10.2321","article-title":"Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae","volume":"40","author":"Pan","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B91","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1128\/AAC.19.1.188","article-title":"Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections","volume":"19","author":"Hirai","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B92","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2165\/00003495-198530060-00003","article-title":"Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use","volume":"30","author":"Holmes","year":"1985","journal-title":"Drugs"},{"key":"2026021903541847700_dkag054-B93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/j.1875-9114.1987.tb04030.x","article-title":"Norfloxacin: clinical pharmacology and clinical use","volume":"7","author":"Rowen","year":"1987","journal-title":"Pharmacotherapy"},{"key":"2026021903541847700_dkag054-B94","doi-asserted-by":"publisher","first-page":"115","DOI":"10.34531\/jjhp.55.2_115","article-title":"History of discovery and development of norfloxacin; a new quinolone antimicrobial agent","volume":"55","author":"Hirai","year":"2020","journal-title":"Jpn J Hist Pharm"},{"key":"2026021903541847700_dkag054-B95","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol"},{"key":"2026021903541847700_dkag054-B96","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1128\/AAC.23.4.559","article-title":"In vitro activity of BAY 09867, a new quinoline derivative, compared with those of other antimicrobial agents","volume":"23","author":"Wise","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B97","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1128\/AAC.24.4.568","article-title":"In vitro activity of ciprofloxacin (BAY o 9867)","volume":"24","author":"Fass","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B98","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF01641358","article-title":"Activity of ciprofloxacin (BAY o 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae","volume":"11","author":"Roy","year":"1983","journal-title":"Infection"},{"key":"2026021903541847700_dkag054-B99","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B100","volume-title":"Norfloxacin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2020"},{"key":"2026021903541847700_dkag054-B101","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1128\/AAC.22.4.548","article-title":"In vitro and in vivo activity of DL-8280, a new oxazine derivative","volume":"22","author":"Sato","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B102","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1185\/03007998709108959","article-title":"Relative bioavailability of ofloxacin tablets in comparison to oral solution","volume":"10","author":"Malerczyk","year":"1987","journal-title":"Curr Med Res Opin"},{"key":"2026021903541847700_dkag054-B103","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2165\/00003088-199222010-00004","article-title":"Ofloxacin clinical pharmacokinetics","volume":"22","author":"Lamp","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"2026021903541847700_dkag054-B104","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","article-title":"The clinical pharmacokinetics of levofloxacin","volume":"32","author":"Fish","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"2026021903541847700_dkag054-B105","author":"Atarashi"},{"key":"2026021903541847700_dkag054-B106","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1128\/AAC.29.1.163","article-title":"Synthesis and antibacterial activities of optically active ofloxacin","volume":"29","author":"Hayakawa","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B107","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B108","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1824-7288-39-34","article-title":"Epidemiology and associations with climatic conditions of Mycoplasma pneumoniae and Chlamydophila pneumoniae infections among Chinese children hospitalized with acute respiratory infections","volume":"39","author":"Chen","year":"2013","journal-title":"Ital J Pediatr"},{"key":"2026021903541847700_dkag054-B109","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2165\/00003495-199447040-00008","article-title":"Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"2026021903541847700_dkag054-B110","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jiac.2017.02.002","article-title":"JAID\/JSC guidelines for clinical management of infectious disease 2015 - urinary tract infection\/male genital infection","volume":"23","author":"Japanese Association for Infectious Disease\/Japanese Society of Chemotherapy; JAID\/JSC Guide\/Guidelines to Clinical Management of Infectious Disease Preparing Committee; Urinary tract infection\/male genital infection working group","year":"2017","journal-title":"J Infect Chemother"},{"key":"2026021903541847700_dkag054-B111","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1442-2042.2010.02500.x","article-title":"Current therapy of acute uncomplicated cystitis","volume":"17","author":"Yamamoto","year":"2010","journal-title":"Int J Urol"},{"key":"2026021903541847700_dkag054-B112","author":"Japanese Association for Infectious Disease\/Japanese Society of Chemotherapy"},{"key":"2026021903541847700_dkag054-B113","doi-asserted-by":"publisher","first-page":"19719","DOI":"10.1038\/s41598-024-70535-y","article-title":"Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study","volume":"14","author":"Nehru","year":"2024","journal-title":"Sci Rep"},{"key":"2026021903541847700_dkag054-B114","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021903541847700_dkag054-B115","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jgar.2020.11.011","article-title":"Fluroquinolone drug resistance among MDR-tb patients increases the risk of unfavourable interim microbiological treatment outcome: an observational study","volume":"24","author":"Singh","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2026021903541847700_dkag054-B116","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1128\/AAC.49.10.4035-4041.2005","article-title":"Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults","volume":"49","author":"D'Ignazio","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B117","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000239474","article-title":"In vitro activity of BAY 12-8039, a new 8-methoxyquinolone","volume":"42","author":"Dalhoff","year":"1996","journal-title":"Chemotherapy"},{"key":"2026021903541847700_dkag054-B118","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1128\/AAC.41.7.1594","article-title":"In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis","volume":"41","author":"Brueggemann","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B119","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/jdv.17972","article-title":"2021 European guideline on the management of Mycoplasma genitalium infections","volume":"36","author":"Jensen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026021903541847700_dkag054-B120","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3201\/eid1207.051558","article-title":"Azithromycin failure in Mycoplasma genitalium urethritis","volume":"12","author":"Bradshaw","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2026021903541847700_dkag054-B121","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1211\/jpp.60.1.0007","article-title":"Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver","volume":"60","author":"Ahmed","year":"2008","journal-title":"J Pharm Pharmacol"},{"key":"2026021903541847700_dkag054-B122","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1124\/jpet.108.142257","article-title":"Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones","volume":"328","author":"Ohta","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2026021903541847700_dkag054-B123","volume-title":"StatPearls [Internet]","author":"Thai","year":"2023"},{"key":"2026021903541847700_dkag054-B124","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B125","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2165\/00003088-199019060-00003","article-title":"Clinical pharmacokinetics of ciprofloxacin","volume":"19","author":"Vance-Bryan","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"2026021903541847700_dkag054-B126","volume-title":"StatPearls [Internet]","author":"Humma","year":"2024"},{"key":"2026021903541847700_dkag054-B127","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00003495-199957030-00007","article-title":"Moxifloxacin","volume":"57","author":"Balfour","year":"1999","journal-title":"Drugs"},{"key":"2026021903541847700_dkag054-B128","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/00003495-200059010-00010","article-title":"Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections","volume":"59","author":"Balfour","year":"2000","journal-title":"Drugs"},{"key":"2026021903541847700_dkag054-B129","author":"DONG WHA News"},{"key":"2026021903541847700_dkag054-B130","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B131","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B132","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1128\/AAC.44.2.283-286.2000","article-title":"Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"44","author":"Tomioka","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B133","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/pharmaceutics13081289","article-title":"Structural characterization of the millennial antibacterial (fluoro)quinolones-shaping the fifth generation","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026021903541847700_dkag054-B134","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B135","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/cid\/ciy600","article-title":"Delafloxacin: a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone","volume":"68","author":"Saravolatz","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"2026021903541847700_dkag054-B136","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1093\/cid\/ciy1079","article-title":"Profile of a novel anionic fluoroquinolone-delafloxacin","volume":"68","author":"Tulkens","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026021903541847700_dkag054-B137","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B138","doi-asserted-by":"publisher","first-page":"e02294-20","DOI":"10.1128\/AAC.02294-20","article-title":"Finafloxacin is an effective treatment for inhalational tularemia and plague in mouse models of infection","volume":"65","author":"Barnes","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B139","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B140","author":"Muller"},{"key":"2026021903541847700_dkag054-B141","doi-asserted-by":"publisher","first-page":"e02317-17","DOI":"10.1128\/AAC.02317-17","article-title":"Explorative randomized phase II clinical study of the efficacy and safety of finafloxacin versus ciprofloxacin for treatment of complicated urinary tract infections","volume":"62","author":"Wagenlehner","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B142","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1093\/jac\/dkq375","article-title":"Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance","volume":"65","author":"Emrich","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B143","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1128\/AAC.00833-10","article-title":"In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions","volume":"55","author":"Stubbings","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B144","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/antibiotics10121506","article-title":"Delafloxacin, finafloxacin, and zabofloxacin: novel fluoroquinolones in the antibiotic pipeline","volume":"10","author":"Kocsis","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026021903541847700_dkag054-B145","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1128\/AAC.01407-05","article-title":"In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone","volume":"50","author":"Park","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B146","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/molecules21111562","article-title":"Antimicrobial activity of zabofloxacin against clinically isolated Streptococcus pneumoniae","volume":"21","author":"Park","year":"2016","journal-title":"Molecules"},{"key":"2026021903541847700_dkag054-B147","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.diagmicrobio.2008.05.010","article-title":"Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains","volume":"62","author":"Jones","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026021903541847700_dkag054-B148","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jac\/dkl304","article-title":"In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent","volume":"58","author":"Kwon","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B149","first-page":"583","article-title":"[Tosufloxacin tosilate]","volume":"43","author":"Shimada","year":"1990","journal-title":"Jpn J Antibiot"},{"key":"2026021903541847700_dkag054-B150","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/11207380-000000000-00000","article-title":"Sitafloxacin: in bacterial infections","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs"},{"key":"2026021903541847700_dkag054-B151","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1358\/dot.2020.56.6.3137167","article-title":"Lascufloxacin hydrochloride to treat bacterial infection","volume":"56","author":"Thakare","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"2026021903541847700_dkag054-B152","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1128\/AAC.36.7.1491","article-title":"Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates","volume":"36","author":"Sato","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B153","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2131\/jts.48.149","article-title":"Effects of early-life tosufloxacin tosilate hydrate administration on growth rate, neurobehavior, and gut microbiota at adulthood in male mice","volume":"48","author":"Hasegawa","year":"2023","journal-title":"J Toxicol Sci"},{"key":"2026021903541847700_dkag054-B154","first-page":"145","article-title":"A case of renal dysfunction caused by an overdose of tosufloxacin tosilate","volume":"25","author":"Matsumura","year":"2013","journal-title":"J Pediatr Infect Dis Immunol"},{"key":"2026021903541847700_dkag054-B155","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/jcph.715","article-title":"Safety concerns surrounding quinolone use in children","volume":"56","author":"Patel","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2026021903541847700_dkag054-B156","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/BPO.0b013e3181982c4f","article-title":"The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model","volume":"29","author":"Sansone","year":"2009","journal-title":"J Pediatr Orthop"},{"key":"2026021903541847700_dkag054-B157","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European society for microbiology and infectious diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026021903541847700_dkag054-B158","author":"Bonkat"},{"key":"2026021903541847700_dkag054-B159","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41579-024-01092-4","article-title":"Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics","volume":"23","author":"Timm","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"2026021903541847700_dkag054-B160","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/pharmaceutics15030804","article-title":"Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile?","volume":"15","author":"Rusu","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026021903541847700_dkag054-B161","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1345\/aph.19305","article-title":"Alatrofloxacin-induced seizures during slow intravenous infusion","volume":"34","author":"Melvani","year":"2000","journal-title":"Ann Pharmacother"},{"key":"2026021903541847700_dkag054-B162","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1345\/aph.19224","article-title":"Severe thrombocytopenia associated with alatrofloxacin","volume":"34","author":"Gales","year":"2000","journal-title":"Ann Pharmacother"},{"key":"2026021903541847700_dkag054-B163","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/PL00011876","article-title":"Acute liver failure due to trovafloxacin: CT findings","volume":"8","author":"Pannu","year":"2001","journal-title":"Emerg Radiol"},{"key":"2026021903541847700_dkag054-B164","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B165","author":"European Medicines Agency"},{"key":"2026021903541847700_dkag054-B166","author":"European Medicines Agency"},{"key":"2026021903541847700_dkag054-B167","author":"U.S. Food and Drug Administration"},{"key":"2026021903541847700_dkag054-B168","author":"European Medicines Agency"},{"key":"2026021903541847700_dkag054-B169","author":"Medicines & Healthcare products Regulatory Agency"},{"key":"2026021903541847700_dkag054-B170","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","article-title":"European Association of Urology guidelines on urological infections: summary of the 2024 guidelines","volume":"86","author":"Kranz","year":"2024","journal-title":"Eur Urol"},{"key":"2026021903541847700_dkag054-B171","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s11606-023-08559-9","article-title":"Antibiotic use in hospital urinary tract infections after FDA regulation","volume":"39","author":"Brant","year":"2024","journal-title":"J Gen Intern Med"},{"key":"2026021903541847700_dkag054-B172","doi-asserted-by":"publisher","first-page":"ofab538","DOI":"10.1093\/ofid\/ofab538","article-title":"Ambulatory fluoroquinolone use in the United States, 2015\u20132019","volume":"8","author":"Umarje","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026021903541847700_dkag054-B173","doi-asserted-by":"publisher","first-page":"e0015121","DOI":"10.1128\/AAC.00151-21","article-title":"Outpatient fluoroquinolone prescription fills in the United States, 2014 to 2020: assessing the impact of food and drug administration safety warnings","volume":"65","author":"Buehrle","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B174","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/pds.5593","article-title":"Outpatient fluoroquinolone use in relation to European Medicines Agency's recommendation: an Estonian nationwide drug utilization study","volume":"32","author":"Kurvits","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026021903541847700_dkag054-B175","author":"Grabe"},{"key":"2026021903541847700_dkag054-B176","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2026021903541847700_dkag054-B177","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jgar.2018.04.017","article-title":"Determination of GyrA and parC mutations and prevalence of plasmid-mediated quinolone resistance genes in Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infection in Iran","volume":"13","author":"Mirzaii","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2026021903541847700_dkag054-B178","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.3390\/molecules25235662","article-title":"Quinolones: mechanism, lethality and their contributions to antibiotic resistance","volume":"25","author":"Bush","year":"2020","journal-title":"Molecules"},{"key":"2026021903541847700_dkag054-B179","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1128\/AAC.34.6.1271","article-title":"Quinolone resistance-determining region in the DNA gyrase GyrA gene of Escherichia coli","volume":"34","author":"Yoshida","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B180","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1021\/bi2013905","article-title":"Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance","volume":"51","author":"Aldred","year":"2012","journal-title":"Biochemistry"},{"key":"2026021903541847700_dkag054-B181","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1093\/nar\/gkt124","article-title":"Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance","volume":"41","author":"Aldred","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2026021903541847700_dkag054-B182","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1093\/nar\/gkq1296","article-title":"Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface loops direct the activity of a Qnr protein from a gram-negative bacterium","volume":"39","author":"Xiong","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2026021903541847700_dkag054-B183","doi-asserted-by":"publisher","first-page":"25265","DOI":"10.1074\/jbc.M111.226936","article-title":"Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor","volume":"286","author":"Vetting","year":"2011","journal-title":"J Biol Chem"},{"key":"2026021903541847700_dkag054-B184","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/nar\/gkaa1266","article-title":"Pentapeptide repeat protein QnrB1 requires ATP hydrolysis to rejuvenate poisoned gyrase complexes","volume":"49","author":"Mazurek","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2026021903541847700_dkag054-B185","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nm1347","article-title":"Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase","volume":"12","author":"Robicsek","year":"2006","journal-title":"Nat Med"},{"key":"2026021903541847700_dkag054-B186","doi-asserted-by":"publisher","first-page":"1409272","DOI":"10.3389\/fmicb.2024.1409272","article-title":"Longitudinal molecular analysis of clinical and fecal Escherichia coli isolates at a Veterans Affairs Medical Center in Minnesota, USA, 2012-2019","volume":"15","author":"Clabots","year":"2024","journal-title":"Front Microbiol"},{"key":"2026021903541847700_dkag054-B187","doi-asserted-by":"publisher","first-page":"104909","DOI":"10.1016\/j.ebiom.2023.104909","article-title":"Gut microbiome predictors of Escherichia coli sequence type 131 colonization and loss","volume":"99","author":"Park","year":"2024","journal-title":"EBioMedicine"},{"key":"2026021903541847700_dkag054-B188","doi-asserted-by":"publisher","first-page":"ofx089","DOI":"10.1093\/ofid\/ofx089","article-title":"The pandemic H30 subclone of sequence type 131 (ST131) as the leading cause of multidrug-resistant Escherichia coli infections in the United States (2011-2012)","volume":"4","author":"Johnson","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2026021903541847700_dkag054-B189","doi-asserted-by":"publisher","first-page":"e00347-16","DOI":"10.1128\/mBio.00347-16","article-title":"Sequential acquisition of virulence and fluoroquinolone resistance has shaped the evolution of Escherichia coli ST131","volume":"7","author":"Ben Zakour","year":"2016","journal-title":"mBio"},{"key":"2026021903541847700_dkag054-B190","doi-asserted-by":"publisher","first-page":"e02162","DOI":"10.1128\/mBio.02162-15","article-title":"Evolutionary history of the global emergence of the Escherichia coli epidemic clone ST131","volume":"7","author":"Stoesser","year":"2016","journal-title":"mBio"},{"key":"2026021903541847700_dkag054-B191","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.eimc.2013.01.004","article-title":"Escherichia coli ST131: variations on a theme of clonal expansion","volume":"31","author":"Banerjee","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2026021903541847700_dkag054-B192","doi-asserted-by":"publisher","first-page":"e00346-20","DOI":"10.1128\/AAC.00346-20","article-title":"Antimicrobial susceptibility and cross-resistance patterns among common complicated urinary tract infections in U.S. Hospitals, 2013 to 2018","volume":"64","author":"Zilberberg","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B193","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1159\/000361011","article-title":"High prevalence of cross-resistance to aminoglycosides in fluoroquinolone-resistant Escherichia coli clinical isolates","volume":"59","author":"Tsukamoto","year":"2013","journal-title":"Chemotherapy"},{"key":"2026021903541847700_dkag054-B194","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3201\/eid0606.000604","article-title":"Trends in antimicrobial-drug resistance in Japan","volume":"6","author":"Arakawa","year":"2000","journal-title":"Emerg Infect Dis"},{"key":"2026021903541847700_dkag054-B195","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jiac.2015.05.014","article-title":"Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases","volume":"21","author":"Ishikawa","year":"2015","journal-title":"J Infect Chemother"},{"key":"2026021903541847700_dkag054-B196","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jiac.2020.01.004","article-title":"The third national Japanese antimicrobial susceptibility pattern surveillance program: bacterial isolates from complicated urinary tract infection patients","volume":"26","author":"Kobayashi","year":"2020","journal-title":"J Infect Chemother"},{"key":"2026021903541847700_dkag054-B197","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jiac.2024.03.024","article-title":"Fourth national Japanese antimicrobial susceptibility pattern surveillance program: bacterial isolates from patients with complicated urinary tract infections","volume":"30","author":"Kobayashi","year":"2024","journal-title":"J Infect Chemother"},{"key":"2026021903541847700_dkag054-B198","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jiac.2019.03.008","article-title":"Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2016","volume":"25","author":"Tateda","year":"2019","journal-title":"J Infect Chemother"},{"key":"2026021903541847700_dkag054-B199","author":"The Government of Japan"},{"key":"2026021903541847700_dkag054-B200","author":"The Goverment of Japan"},{"key":"2026021903541847700_dkag054-B201","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1128\/AAC.00786-15","article-title":"High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014","volume":"59","author":"Unemo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B202","author":"ClinicalTrials.gov"},{"key":"2026021903541847700_dkag054-B203","author":"ClinicalTrials.gov"},{"key":"2026021903541847700_dkag054-B204","author":"ClinicalTrials.gov"},{"key":"2026021903541847700_dkag054-B205","author":"GSK"},{"key":"2026021903541847700_dkag054-B206","author":"Spero Therapeutics"},{"key":"2026021903541847700_dkag054-B207","author":"ClinicalTrials.gov"},{"key":"2026021903541847700_dkag054-B208","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jac\/dkab024","article-title":"High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018","volume":"76","author":"Unemo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B209","author":"Innoviva Specialty Therapeutics"},{"key":"2026021903541847700_dkag054-B210","doi-asserted-by":"publisher","first-page":"11827","DOI":"10.1038\/srep11827","article-title":"Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases","volume":"5","author":"Basarab","year":"2015","journal-title":"Sci Rep"},{"key":"2026021903541847700_dkag054-B211","author":"Drugs for Neglected Diseases initiative"},{"key":"2026021903541847700_dkag054-B212","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1128\/AAC.03090-14","article-title":"High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea","volume":"58","author":"Jacobsson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B213","doi-asserted-by":"publisher","first-page":"e01479-19","DOI":"10.1128\/AAC.01479-19","article-title":"High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015-2017)","volume":"63","author":"Jacobsson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B214","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1128\/AAC.04124-14","article-title":"In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase\/topoisomerase inhibitor with potent activity against gram-positive, fastidious gram-negative, and atypical bacteria","volume":"59","author":"Huband","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B215","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.05.018","article-title":"In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione","volume":"48","author":"Papp","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2026021903541847700_dkag054-B216","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1128\/AAC.01211-15","article-title":"Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914)","volume":"60","author":"Su","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B217","doi-asserted-by":"publisher","first-page":"e0092724","DOI":"10.1128\/aac.00927-24","article-title":"Local emergence and global evolution of Neisseria gonorrhoeae with high-level resistance to azithromycin","volume":"68","author":"Melendez","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B218","doi-asserted-by":"publisher","first-page":"255","DOI":"10.15585\/mmwr.mm7312a2","article-title":"Ceftriaxone-resistant gonorrhea - China, 2022","volume":"73","author":"Zhu","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026021903541847700_dkag054-B219","doi-asserted-by":"publisher","first-page":"dlae053","DOI":"10.1093\/jacamr\/dlae053","article-title":"High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022-23: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)","volume":"6","author":"Ouk","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026021903541847700_dkag054-B220","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/1471-2334-14-433","article-title":"Incidence and antimicrobial susceptibility of Neisseria gonorrhoeae isolates from patients attending the national Neisseria gonorrhoeae reference laboratory of Hungary","volume":"14","author":"Brunner","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2026021903541847700_dkag054-B221","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10156-008-0610-7","article-title":"Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone","volume":"14","author":"Osaka","year":"2008","journal-title":"J Infect Chemother"},{"key":"2026021903541847700_dkag054-B222","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"2026021903541847700_dkag054-B223","doi-asserted-by":"publisher","first-page":"e0152522","DOI":"10.1128\/aac.01525-22","article-title":"Antimicrobial activity of gepotidacin tested against Escherichia coli and Staphylococcus saprophyticus isolates causing urinary tract infections in medical centers worldwide (2019 to 2020)","volume":"67","author":"Arends","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B224","author":"Mushtaq"},{"key":"2026021903541847700_dkag054-B225","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/jac\/dky162","article-title":"In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae","volume":"73","author":"Jacobsson","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026021903541847700_dkag054-B226","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s40121-023-00862-6","article-title":"Efficacy and safety of gepotidacin as treatment of uncomplicated urogenital gonorrhea (EAGLE-1): design of a randomized, comparator-controlled, phase 3 study","volume":"12","author":"Perry","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026021903541847700_dkag054-B227","doi-asserted-by":"publisher","first-page":"e0120821","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B228","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1021\/acsinfecdis.0c00025","article-title":"Advancement of GyrB inhibitors for treatment of infections caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria","volume":"6","author":"Stokes","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2026021903541847700_dkag054-B229","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"2026021903541847700_dkag054-B230","doi-asserted-by":"publisher","first-page":"e0132121","DOI":"10.1128\/spectrum.01321-21","article-title":"In vitro resistance against DNA gyrase inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus","volume":"10","author":"Aragaw","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2026021903541847700_dkag054-B231","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections","volume":"59","author":"Locher","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021903541847700_dkag054-B232","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/14787210.2023.2270158","article-title":"Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720","volume":"21","author":"Winthrop","year":"2023","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag054\/66988924\/dkag054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag054\/66988924\/dkag054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:54:24Z","timestamp":1771491264000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag054\/8490223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":232,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag054","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag054"}}